What is Chardan Capital’s Forecast for STOK FY2025 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Chardan Capital issued their FY2025 EPS estimates for Stoke Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the company will post earnings per share of ($1.75) for the year. Chardan Capital currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and a consensus price target of $24.67.

Stoke Therapeutics Stock Down 4.4 %

STOK opened at $7.40 on Thursday. The stock has a market capitalization of $400.18 million, a price-to-earnings ratio of -3.52 and a beta of 0.99. Stoke Therapeutics has a twelve month low of $7.18 and a twelve month high of $17.58. The company has a 50-day simple moving average of $9.40 and a 200 day simple moving average of $11.27.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,532 shares of company stock worth $143,332. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after purchasing an additional 471,240 shares during the last quarter. Baker BROS. Advisors LP grew its position in shares of Stoke Therapeutics by 6.1% in the 4th quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after buying an additional 265,395 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $35,001,000. State Street Corp raised its position in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after acquiring an additional 38,446 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.